UNSPSC 51442417: Iofetamine i-123

This classification denotes a contrast media with the molecular formula C12H18IN, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) LV23B78IJC, chemically known as 1-(4-iodanylphenyl)-N-propan-2-ylpropan-2-amine but more generally known as Iofetamine i-123, which bears U.S. National Institutes of Health Compound Identifier 156375.

UNSPSC 51442417 Iofetamine I-123 (Commodity) shows minimal alignment with recent state and local procurement activity. The code nominates a specific radiopharmaceutical — iofetamine I-123, a diagnostic imaging agent — but the recent opportunities tagged under it span radiologic equipment procurement, X-ray system maintenance and warranties, and copper sulfate supply, none of which match the code's actual scope. State and local governments do not appear to be actively soliciting iofetamine I-123 or related radiopharmaceuticals through posted contract opportunities at present. The mismatch between the code's nomination and the actual work being bought suggests either miscoding in source records or dormant procurement activity under this specific commodity.

The few opportunities in the dataset — Maricopa County's radiologic equipment and installation IFB (due October 22, 2026), Escambia County Correction's extended warranty RFQ for X-ray equipment (due August 19, 2026), Broward County Aviation Department's RFI on Rapiscan X-ray system maintenance services (due July 28, 2026), and Pasco County's copper sulfate supply RFQ (due June 26, 2026) — are unrelated to radiopharmaceutical procurement and do not support a reliable picture of market activity under this Commodity code. No repeat buyers, geographic concentration, or sustained demand signal emerges from these records. Firms pursuing iofetamine I-123 sales to state and local healthcare systems should monitor procurement channels directly rather than relying on UNSPSC coding in this category.